Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia

被引：69
|
作者：
Zugmaier, G. [1 ]
Topp, M. S. [2 ,3 ]
Alekar, S. [4 ]
Viardot, A. [5 ]
Horst, H-A [6 ,7 ]
Neumann, S. [6 ,7 ]
Stelljes, M. [8 ]
Bargou, R. C. [3 ]
Goebeler, M. [3 ]
Wessiepe, D. [9 ]
Degenhard, E. [1 ]
Goekbuget, N. [10 ]
Klinger, M. [1 ]
机构：
[1] Amgen Res Munich GmbH, Munich, Germany
[2] Univ Klinikum Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany
[3] Univ Klinikum Wurzburg, Comprehens Canc Ctr Mainfranken, Wurzburg, Germany
[4] Amgen Inc, Thousand Oaks, CA 91320 USA
[5] Univ Ulm, Dept Med 3, D-89069 Ulm, Germany
[6] City Hosp, Dept Med 2, Kiel, Germany
[7] Univ Hosp Schleswig Holstein, Kiel, Germany
[8] Univ Munster, Bone Marrow Transplantat Ctr, D-48149 Munster, Germany
[9] Metronomia GmbH, Munich, Germany
[10] Goethe Univ Frankfurt, Ctr Internal Med, Frankfurt, Germany
来源：
BLOOD CANCER JOURNAL | 2014年 / 4卷
关键词：
STEM-CELL TRANSPLANTATION; ENGAGING ANTIBODY; FREE SURVIVAL; RITUXIMAB; LYMPHOMA; HYPOGAMMAGLOBULINEMIA; LINEAGE;
D O I：
10.1038/bcj.2014.64
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：e244 / e244
页数：4
相关论文
共 50 条
  • [21] Estimating Long-Term Survival of Adults with Philadelphia Chromosome-Negative Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia Treated with Blinatumomab Using Historical Data
    Barlev, Arie
    Lin, Vincent W.
    Katz, Aaron
    Hu, Kuolung
    Cong, Ze
    Barber, Beth
    ADVANCES IN THERAPY, 2017, 34 (01) : 148 - 155
  • [22] Health-Related Quality of Life in Adults with B-Cell Precursor Acute Lymphoblastic Leukemia and Minimal Residual Disease Treated with Blinatumomab
    Bargou, Ralf C.
    Zugmaier, Gerhard
    Bonifacio, Massimiliano
    Graux, Carlos
    Faul, Christoph
    Topp, Max S.
    Qui Tran
    Zhang, Xinke
    Goekbuget, Nicola
    BLOOD, 2018, 132
  • [23] Very long-term molecular follow-up of minimal residual disease in patients with neuroblastoma
    Tchirkov, Andrei
    Greze, Victoria
    Plantaz, Dominique
    Rouel, Nadege
    Vago, Philippe
    Kanold, Justyna
    PEDIATRIC BLOOD & CANCER, 2018, 65 (12)
  • [24] Day 15 Bone Marrow Minimal Residual Disease (MRD) Predicts Response to Blinatumomab in Relapsed/Refractory Pediatric B-Precursor Acute Lymphoblastic Leukemia (B-ALL)
    Browns, P.
    Zugmaier, G.
    Gore, L.
    Tuglus, C. A.
    von Stackelberg, A.
    PEDIATRIC BLOOD & CANCER, 2018, 65 : S6 - S7
  • [25] Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia
    Goekbuget, Nicola
    Dombret, Nerve
    Giebel, Sebastian
    Bruggemann, Monika
    Doubek, Michael
    Foa, Robin
    Hoelzer, Dieter
    Kim, Christopher
    Martinelli, Giovanni
    Parovichnikova, Elena
    Rambaldi, Alessandro
    Ribera, Josep-Maria
    Schoonen, Marieke
    Stieglmaier, Julia M.
    Zugmaier, Gerhard
    Bassan, Renato
    HEMATOLOGY, 2019, 24 (01) : 337 - 348
  • [26] Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia
    Pui, CH
    Cheng, C
    Leung, W
    Rai, SN
    Rivera, GK
    Sandlund, JT
    Ribeiro, RC
    Relling, MV
    Kun, LE
    Evans, WE
    Hudson, MM
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (07): : 640 - 649
  • [27] Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia
    Goekbuget, Nicola
    Zugmaier, Gerhard
    Klinger, Matthias
    Kufer, Peter
    Stelljes, Matthias
    Viardot, Andreas
    Horst, Heinz A.
    Neumann, Svenja
    Brueggemann, Monika
    Ottmann, Oliver G.
    Burmeister, Thomas
    Wessiepe, Dorothea
    Topp, Max S.
    Bargou, Ralf
    HAEMATOLOGICA, 2017, 102 (04) : E132 - E135
  • [28] PSYCHOLOGICAL PROGNOSTIC FACTORS IN PATIENTS WITH ACUTE LYMPHOBLASTIC-LEUKEMIA - LONG-TERM FOLLOW-UP
    FISMAN, N
    SANTARELLI, MT
    PAVLOVSKY, S
    GARAY, G
    GENERAL HOSPITAL PSYCHIATRY, 1991, 13 (06) : 369 - 370
  • [29] Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels
    Inoue, K
    Ogawa, H
    Yamagami, T
    Soma, T
    Tani, Y
    Tatekawa, T
    Oji, Y
    Tamaki, H
    Kyo, T
    Dohy, H
    Hiraoka, A
    Masaoka, T
    Kishimoto, T
    Sugiyama, H
    BLOOD, 1996, 88 (06) : 2267 - 2278
  • [30] Comparison between fusion transcripts and leukemia-associated immunophenotypes as markers of minimal residual disease in B-precursor acute lymphoblastic leukemia
    Huang, Y. J.
    Kao, H. W.
    Coustan-Smith, E.
    Liu, H. C.
    Chen, S. H.
    Yang, C. P.
    Hsiao, C. C.
    Yeh, T. C.
    Kuo, M. C.
    Lai, C. L.
    Chang, C. H.
    Campana, D.
    Liang, D. C.
    Shih, L. Y.
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 : 76 - 76
12345